Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1995 Sep;50(3):560-86.
doi: 10.2165/00003495-199550030-00009.

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease

Affiliations
Review

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease

M Haria et al. Drugs. 1995 Sep.

Erratum in

  • Drugs 1995 Nov;50(5):896

Abstract

Amlodipine belongs to the dihydropyridine class of calcium channel blockers. Both short and long term studies indicate that amlodipine effectively lowers mild to moderately elevated blood pressure and relieves symptoms of angina pectoris. In comparative studies, its antihypertensive efficacy is similar to that of other established agents such as beta-blockers, diuretics, ACE inhibitors and other calcium channel blockers (including the dihydropyridines); limited comparative data are, however, available in patients with angina pectoris. Amlodipine may offer potential in patients with congestive heart failure. Vasodilator adverse events such as oedema, headaches, and flushing are commonly observed with amlodipine. The drug does not appear to cause postural hypotension, reflex tachycardia or cardiac conduction disturbances. Comparative studies suggest that amlodipine is at least as well tolerated as other standard agents. Thus, amlodipine provides an attractive therapeutic option for the treatment of hypertension, and offers potential for patients with angina pectoris. Its beneficial effects in patients with congestive heart failure require confirmation in future studies.

PubMed Disclaimer

References

    1. Lancet. 1993 Jan 30;341(8840):306 - PubMed
    1. Br J Clin Pharmacol. 1986 Jul;22(1):21-5 - PubMed
    1. Am J Hypertens. 1989 Jul;2(7):537-41 - PubMed
    1. Postgrad Med J. 1991;67 Suppl 5:S54-6 - PubMed
    1. Lancet. 1994 Jul 9;344(8915):101-6 - PubMed

MeSH terms